You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Expert Recommendations for Treating Newly Diagnosed High-Risk AML

  • Authors: Geoffrey L. Uy, MD; Ashley Leak Bryant, PhD, RN-BC, OCN; Amanda N. Seddon, PharmD, BCPS, BCOP
  • CME / ABIM MOC / CE Released: 9/25/2019
  • Valid for credit through: 9/25/2020
Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses/nurse practitioners, and pharmacists. 

The goal of this activity is to increase knowledge and improve competence related to team-based management of patients with newly diagnosed high-risk acute myeloid leukemia (AML).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Post-allogeneic hematopoietic stem cell transplant (HSCT) outcomes associated with various consolidation regimens used for high-risk AML
  • Have greater competence related to
    • Tailoring induction and consolidation regimens for individual patients with newly diagnosed high-risk AML 
    • Integrating novel agents and formulations into clinical practice for the treatment of high-risk AML 
  • Demonstrate greater confidence in their ability to
    • Provide team-based care for patients with newly diagnosed high-risk AML


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Geoffrey L Uy, MD

    Associate Professor of Medicine
    Oncology Division
    Washington University School of Medicine
    St. Louis, Missouri


    Disclosure: Geoffrey L. Uy, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Astellas Pharma, Inc.


  • Ashley Leak Bryant, PhD, RN-BC, OCN

    Assistant Professor
    School of Nursing
    Clinical Nurse
    North Carolina Cancer Hospital
    UNC Lineberger Comprehensive Cancer Center
    The University of North Carolina at Chapel Hill


    Disclosure: Ashley Leak Bryant, PhD, RN-BC, OCN, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Carevive Systems, Inc.
    Received grants for clinical research from: Carevive Systems, Inc.

  • Amanda N Seddon, PharmD, BCPS, BCOP

    Assistant Professor
    Midwestern University Chicago College of Pharmacy
    Clinical Pharmacy Specialist
    Rush University Medical Center
    Chicago, Illinois


    Disclosure: Amanda N. Seddon, PharmD, BCPS, BCOP, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: Merck & Co., Inc.; Portola Pharmaceuticals, Inc.


  • Mindy Tanzola, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

  • Vandana Iyer, PhD

    Scientific Content Manager, Medscape, LLC


    Disclosure: Vandana Iyer, PhD, has disclosed no relevant financial relationships.

CME/CE Reviewer, Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-19-461-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Expert Recommendations for Treating Newly Diagnosed High-Risk AML

Authors: Geoffrey L. Uy, MD; Ashley Leak Bryant, PhD, RN-BC, OCN; Amanda N. Seddon, PharmD, BCPS, BCOPFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/25/2019

Valid for credit through: 9/25/2020



AE = adverse event
AML = acute myeloid leukemia
ANC = absolute neutrophil count
AR = allelic ratio
AZA = azacitidine
BM = bone marrow
CBC = complete blood count
CBF = core binding factor
CEBPA = CCAAT/enhancer-binding protein alpha
chemo = chemotherapy
DEC = decitabine
CI = confidence interval
CPX-351 = liposomal cytarabine-daunorubicin
CR = complete remission
CR1 = first complete remission
CRi = complete response with incomplete neutrophil or platelet recovery
DFS = disease-free survival
DLBCL = diffuse large B-cell lymphoma
DNMT3A = DNA methyltransferase 3 alpha
ECOG = Eastern Cooperative Oncology Group 
EFS = event-free survival
FDA = US Food and Drug Administration
FLT3 = fms-like tyrosine kinase 3
Hgb = hemoglobin
HiDAC = high-dose cytarabine
HLA = human leukocyte antigen
HMA = hypomethylating agent
HR = hazard ratio
HSCT = hematopoietic stem cell transplant
IC = intensive chemotherapy
IDH = isocitrate dehydrogenase
IV = intravenous
ITD = internal tandem duplication
LDAC = low-dose cytarabine 
LDH = lactate dehydrogenase
MDS = myelodysplastic syndrome
MLL = mixed lineage leukemia
mOS = median overall survival
MPN = myeloproliferative neoplasm
ND = newly diagnosed
NPM1 = nucleophosmin
NR = not reached
OS = overall survival
OT = occupational therapy
PS = performance status
PT = physical therapy
R = right
R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
R/R = relapsed/refractory
SCT = stem cell transplant
SOS = sinusoidal obstruction syndrome
tAML = therapy-related AML
TLS = tumor lysis syndrome
TP53 = tumor protein p53
WBC = white blood cell
WT = wildtype

« Return to: Expert Recommendations for Treating Newly Diagnosed High-Risk AML
  • Print